Abstract: The present invention provides pharmaceutical compositions and methods of treating Covid-19 infectious disease. The present invention also provides pharmaceutical compositions and methods of prophylaxis or prophylactic treatment of Covid-19 infectious disease. The said methods involve administering compositions comprising therapeutically effective amount of Cannabidiol thereby causing enhancement/augmentation of innate immunity of the patient/mammal/human.

Abstract: The present invention provides pharmaceutical compositions and methods of treating Covid-19 infectious disease. The present invention also provides pharmaceutical compositions and methods of prophylaxis or prophylactic treatment of Covid-19 infectious disease. The said methods involve administering compositions comprising therapeutically effective amount of Cannabidiol thereby causing enhancement/augmentation of innate immunity of the patient/mammal/human due to at least one of the following effects, i) infected patient cells undergo apoptosis early after infection; ii) induction of interferon transcription in the patient; iii) induction of interferon-induced antiviral effectors in the patient.

Abstract: The present disclosure relates to the modulation of glucagon-like peptide 1 (GLP-1) with inhibitors of lysophosphatidic acid (LPA). LPAR antagonists such as Ki16425, BMS-986020, SAR 100842, AM966, AM095, H2L5186303, LPA2-antagonist 1 and combinations thereof are used in the treatment or prevention of diseases characterized by reduced GLP-1 activity such as: diabetes, Alzheimer's disease, Parkinson's disease, kidney disease (including chronic kidney disease), diabetic nephropathy, a serious renal event, cardiovascular disease, stroke, depression, metal health, pulmonary fibrosis, obesity, aging, or non-alcoholic fatty liver disease.